We offer you three different types of package which allow you to choose based on your demand and possibilities.
- Freezing and storage umbilical cord blood for 20 years
If you want give a better chance in case of a therapy besides umbilical cord blood ask for freezing of umbilical cord as well!
- Freezing and storage umbilical cord blood and cord tissue for 20 years – BASIC service
In our basic service package we freeze the segment rich in mesenchymal stem cells in 4 separate vials.
If you want to take advantage of our world-level protocols developed by the PBKM Institute (Polish Polski Bank Komórek Macierzystych S.A ) choose our PREMIUM service!
- Freezing and storage umbilical cord blood and cord tissue for 20 years – PREMIUM service
In our premium service we isolate and identify the segment rich in mesenchymal stem cells using the special procedure developed by the Fami Cord Group. The process takes at least 5 weeks and 5 separate vials are used for the final storage.
- Get to know more about the advantages of preserving umbilical cord!
What is Wharton’s jelly?
Wharton’s jelly is the tissue, or matrix, of the umbilical cord containing the blood vessels. These blood vessels can be used for collecting UCB-derived stem cells (see figure).
What is the difference between the mesenchymal stem cells collected from Wharton’s jelly and the UCB-derived stem cells?
Wharton’s jelly contains primarily mesenchymal stem cells, while the UCB contains other kind of stem cells (haematopoietic stem cells, endothelial progenitor cells), too. Considering the unit quantity, the number of mesenchymal stem cells is much higher in Wharton’s jelly, than in the UCB.
Why is it worth preserving the Wharton’s jelly-derived stem cells, too?
The reason is that, in case of incidental therapeutic use, these stem cells support the adhesion of UCB-derived stem cells effectively. Their impact mechanism is not fully known yet, but due to their antiphlogistic and immunosuppressive effect, there are several examples of using Wharton’s jelly-derived stem cells together with UCB-derived ones. Therapies using exclusively mesenchymal stem cells for treating GVHD (graft versus host disease) and juvenile diabetes (diabetes mellitus type 1 – T1DM) are undergoing clinical trials. Cultures of mesenchymal stem cells are easy to grow and, hence, practically smaller amounts can be used to generate masses of cells that can be effectively used in later therapies as well.